Mark Frohlich (Indapta Therapeutics)
Overview
Mark W. Frohlich, M.D., is a medical oncologist specializing in the field of immunotherapy and cellular therapy, known primarily for his leadership role as CEO of Indapta Therapeutics. Indapta is a biotechnology company focused on developing unconventional natural killer (NK) cell therapies aimed at treating various types of cancer and autoimmune diseases. Dr. Frohlich's career has been highlighted by his contributions to the development of pioneering therapies at multiple biotechnology firms, leveraging his background in medical oncology and experience in drug development.
Recent Developments
- April 2025: Mark Frohlich joins the board of directors for Rigel Pharmaceuticals, aiming to contribute his expertise in translational research and clinical drug development as Rigel expands its hematology and oncology pipeline source.
- December 2024: Indapta Therapeutics secures $22.5 million in financing to advance its allogeneic Natural Killer (NK) cell therapy trials, announcing plans for further trial expansions in cancer and autoimmune diseases source.
- March 2025: Frohlich outlines Indapta's strategic goals to demonstrate clinical proof of concept for its cancer trials, as well as its intention to push the boundaries of immunotherapy using NK cells source.
- January 2024: Indapta treats its first patients with its NK cell therapy in Phase 1 trials targeting multiple myeloma and non-Hodgkin lymphoma, marking a significant milestone in Frohlich's leadership tenure source.
- November 2024: The company presents promising preclinical and early clinical data at the Society for Immunotherapy of Cancer meeting, showcasing the efficacy of its g-NK cells source.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Mark W. Frohlich, M.D. |
| Born | Not publicly available |
| Nationality | American |
| Occupation | Medical Oncologist, CEO of Indapta Therapeutics |
| Known For | Cellular immunotherapy development |
| Net Worth | Not publicly disclosed |
| Education | M.D., Harvard Medical School; B.S., Yale College |
Early Life and Education
Mark Frohlich has a robust background in medicine, having graduated from Yale College with a Bachelor of Science degree in Electrical Engineering and Economics. He continued his education at Harvard Medical School, where he earned his Doctor of Medicine degree. Frohlich further honed his medical expertise during his residency at the University of California, San Francisco (UCSF), where he specialized in hematology and oncology. His clinical experience and academic achievements laid a strong foundation for his future endeavors in medical research and biotechnology.
Career and Notable Achievements
Mark Frohlich’s career is marked by significant achievements in the biotech industry:
- Dendreon Corporation: As Chief Medical Officer, Frohlich led the approval of PROVENGE®, the first FDA-approved cancer immunotherapy for prostate cancer.
- Juno Therapeutics: Contributed to the strategic development of Breyanzi®, a CAR T-cell therapy approved for large B-cell lymphoma, before its acquisition by Celgene.
- Indapta Therapeutics: Appointed CEO in 2022, he spearheaded the development of the company’s NK cell therapy, achieving several milestones in clinical trials and regulatory advancements.
Current Work and Impact
As of April 2025, Mark Frohlich is actively leading Indapta Therapeutics, focusing on expanding the clinical applications of their NK cell platform. Under his leadership, Indapta aims to revolutionize cancer treatment by providing off-the-shelf immune cell therapies that are more accessible, safer, and potentially more effective than existing treatments. His impact resonates through the biotech community as he continues to foster innovation in immunotherapy and expand access to pioneering treatment options.
Conclusion
Mark Frohlich’s contributions to the field of cellular immunotherapy are significant and ongoing. By leading Indapta Therapeutics through major clinical developments and fundraising efforts, he has positioned the company at the forefront of cancer and autoimmune disease treatments. As he continues to influence the industry through strategic roles, including his recent appointment to the board of Rigel Pharmaceuticals, Frohlich's legacy in biotechnology promises lasting impacts on patient care and therapeutic methodologies.